Table 5. Reporting ratesa of suspected and/or confirmed anaphylaxis following COVID-19 vaccination in non-PICs and PICs in the Western Pacific Region, 1 March 2021–31 March 2022.
| - | Non-PICs | PICs | Total |
|---|---|---|---|
| No. of reporting countries | 14 | 17 | 31 |
| No. of anaphylaxis cases | 7563 | 3 | 7566 |
| COVID-19 vaccineb | Anaphylaxis reporting rate (cases per 1 million doses administered) | ||
| Pfizer-BioNTech | 13.7 | 1.3 | 13.7 |
| Moderna | 8.9 | 0.0 | 8.9 |
| AstraZeneca | 10.0 | 2.6 | 9.9 |
| Johnson & Johnson | 5.7 | 0.0 | 5.6 |
| Gamaleya | 1.6 | NA | 1.6 |
| Sinovac | 1.5 | NA | 1.5 |
| Sinopharm | 0.3 | 0.0 | 0.3 |
NA: not applicable; PICs: Pacific island countries and areas.
a In cases where either the numerator (number of events) or the denominator (number of doses administered) was not available separately (i.e. disaggregated by vaccine), or where there were no available data, data were excluded from computation of the AEFI rates.
b Novavax is not included as its rollout only began in February 2022. By the end of March 2022, 14 cases of anaphylaxis had been reported.